Beijing, China, July 9, 2026 — Jacobio Pharma (1167.HK) today announced that JAR-2203 Injection, independently developed by its associate company Beijing Jacoray Pharmaceutical Technology Co., Ltd. (“Jacoray”)  , has received approval from the Center for Drug Evaluation of China’s National Medical Products Administration to initiate a Phase I clinical trial in China for the treatment of hyperlipoproteinemia(a).

JAR-2203 Injection is an important cardiovascular and metabolic disease program developed by Jacoray. The IND clearance marks the program’s entry into clinical development and reflects the continued advancement of Jacobio’s early-stage innovation projects through external collaboration and resource optimization.

Jacoray is Jacobio’s platform company for early-stage cardiovascular programs. In 2025, Jacobio entered into a transaction with Oceanpine Capital and an industry partner. Upon completion of the transaction, Beijing Jacobio, Oceanpine Capital and the industry partner will hold 10%, 80% and 10% equity interests in Jacoray, respectively.

About Jacobio 
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.

For more information, please visit: http: